A Phase 1 interventional study of Sunitinib (Sutent) and Taxotere in Breast Neoplasms, sponsored by Pfizer. Completed at 3 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-12-23.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing sunitinib in Breast Neoplasms — 1 open to participants now, 2 under way, none of them phase 3. Sunitinib · Breast Neoplasms.
Among the 29 studies testing sunitinib in Breast Neoplasms, this one is the 20th largest by enrollment, is one of 6 that started in 2006, is one of 4 in phase 1, and was the 6th registered.
14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →1 of the 29 studies testing sunitinib in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:
University Medical Center Groningen · Sites in Netherlands
Ages 65+
By country, each count listing its studies:
Sunitinib: first FDA approval 2006 (SUTENT), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 18 · Phase 3 4 · Phase 4 1
First in 2004; this study’s year is marked. 6 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 72 across 10,911 interventional studies indexed under Breast Neoplasms.
Median enrollment 60 across the 29 interventional studies. Of the 25 that completed or were terminated, 18 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 29 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 146 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
182 studies in Breast Neoplasms by Pfizer: 6 open now, 26 under way, 7 of them phase 3. Of 145 finished, 94 (65%) have results posted.
Among the 182 studies in Breast Neoplasms by Pfizer, this one is the 103rd largest by enrollment of the 121 interventional ones that give a count, is one of 9 that started in 2006, is one of 37 in phase 1, and was the 25th registered.
Pfizer’s Breast Neoplasms studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 29 studies testing sunitinib in Breast Neoplasms, from their registry updates:
Among Pfizer’s 182 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study is to evaluate the safety of SU011248 (Sunitinib/Sutent) in combination with docetaxel in patients with metastatic or locally recurrent breast cancer who have not received chemotherapy treatment in the advanced disease setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Sunitinib (Sutent) · Drug: Taxotere
Sunitinib (Sutent) 37.5 mg in schedule 2/1; Sunitinib (Sutent) 37.5 mg in continuous dosing (post discontinuation of axotere) and in accordance with Investigator decision
Also known as: Sutent
Taxotere 75 mg/m2 iv, once every 3 weeks
Time to Reach Maximum Plasma Concentration (Tmax): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters
Median Tmax = time for maximum plasma concentration (Cmax) for SU011248, SU012662, and combined SU011248 and SU012662 (total drug); collected C1D2, C2D3. Paired observation.
Time frame: 1, 2, 4, 6, 8, 12, 24 hours postdose
Maximum Observed Plasma Concentration (Cmax): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters
Mean Cmax = maximum plasma concentration for SU011248, SU012662, and combined SU011248 and SU012662 (total drug) measured as nanograms per milliliter (ng/mL); collected C1D2, C2D3. Paired observation; Cmax dose corrected C2D3 (dose correction if predose concentrations of SU011248 or SU012662 were \> 5% of Cmax).
Time frame: 1, 2, 4, 6, 8, 12, 24 hours postdose
Area Under the Plasma Concentration-time Profile From Time Zero (0) to 24 Hours (AUC24): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters
Mean AUC24 = area under plasma concentration-time profile from time 0 to 24 hours for SU011248, SU012662, and combined SU011248 and SU012662 (total drug) measured in nanograms times hour per milliliter (ng\*hr/mL); collected C1D2, C2D3. Paired observation; AUC24 dose corrected C2D3 (dose correction if predose concentrations of SU011248 or SU012662 were \> 5% of Cmax).
Time frame: 1, 2, 4, 6, 8, 12, 24 hours postdose
Area Under the Curve From Time 0 to Last Quantifiable Concentration (AUClast): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters
Mean AUClast = area under the plasma concentration-time profile from time 0 (predose) to the last measurable concentration; collected C1D2, C2D3. Data did not allow calculation of AUClast; not summarized; AUC summarized in outcome measure: Area under the plasma concentration-time curve from time zero (0) to 24 hours (AUC24): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters.
Time frame: 1, 2, 4, 6, 8, 12, 24 hours postdose
Trough Plasma Concentration (Ctrough) at Time Zero (0): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters
Mean Ctrough=plasma concentration-time profile at time 0 (predose); collected C1D2, C1D15, and C2D1. Calculated by setting concentration values below the limit of quantification to zero.
Time frame: 0 hour postdose
Time to Reach Maximum Plasma Concentration (Tmax): Docetaxel PK Parameters
Median Tmax = time to maximum plasma concentration (Cmax) for Docetaxel; collected C1D1, C2D1. Paired observation.
Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 32, 48 hours postdose
Maximum Observed Plasma Concentration (Cmax): Docetaxel PK Parameters
Mean Cmax = maximum plasma concentration for Docetaxel; collected C1D1, C2D1. Paired observation; Cmax dose corrected (dose correction if predose concentrations of SU011248 or SU012662 were \> 5% of Cmax).
Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 32, 48 hours postdose
Area Under the Plasma Concentration-time Curve From Time Zero (0) to 24 Hours (AUC24): Docetaxel PK Parameters
Mean AUC24 = area under the plasma concentration-time profile from time 0 to 24 hours; collected C1D1, C2D1. Paired observation.
Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 32, 48 hours postdose
Area Under the Plasma Concentration-time Curve From Time Zero (0) to 48 Hours (AUC48): Docetaxel PK Parameters
Mean AUC48 = area under the plasma concentration-time profile from time 0 to 48 hours; collected C1D1, C2D1. Paired observation.
Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 32, 48 hours postdose
Area Under the Curve From Time 24 Hours to 48 Hours (AUC24_48) : Docetaxel PK Parameters
Mean AUC24_48 = area under the plasma concentration-time profile from 24 to 48 hours; collected C1D1, C2D1. Paired observation.
Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 32, 48 hours postdose
Area Under the Curve From Time 0 to Last Quantifiable Concentration (AUClast): Docetaxel PK Parameters
Mean AUClast = area under the plasma concentration-time profile from time 0 (predose) to the last measurable concentration; collected C1D1, C2D1. Paired observation.
Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 32, 48 hours postdose
Plasma Elimination Half-life (t1/2): Docetaxel PK Parameters
Mean Thalf (t1/2) = terminal elimination half life; collected C1D1, C2D1. Paired observation.
Time frame: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 24, 32, 48 hours postdose
Progression-Free Survival (PFS) Based on Investigator Assessment
Median time (50 percent \[%\]) from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first; based on Investigator assessment. PFS calculated as (Weeks) = (first event date minus first dose date plus 1) divided by 7.
Time frame: First dose of study treatment until progressive disease
Number of Subjects With Objective Response of Complete Response or Partial Response Based on Investigator Assessment
Number of subjects with objective response based on Investigator assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response.
Time frame: First dose of study treatment until at least 4 weeks after confirmed response or partial response
Number of Subjects With Clinical Benefit of Complete Response, Partial Response, or Stable Disease Based on Investigator Assessment
Number of subjects with clinical benefit based on Investigator assessment of confirmed complete response (CR), partial response (PR), or stable disease (SD) according to RECIST for at least 24 weeks on study.
Time frame: First dose of study treatment until at least 24 weeks on study
Duration of Tumor Response Based on Investigator Assessment
Median duration (50%) of tumor response based on Investigator assessment for a subgroup of subjects with objective disease response: who have not progressed or died due to any cause; with a response and subsequent progression or death due to any cause for duration of response (DR). DR defined as time from start of first documented objective tumor response (CR or PR) to first documented objective tumor progression or death due to any cause, whichever occurs first. DR calculated as (Weeks) = (the end date for DR minus first subsequent confirmed CR or PR plus 1) divided by 7.
Time frame: Start of first confirmed CR or PR to first confirmed progression or death
| Milestone | Sunitinib in Combination With Docetaxel |
|---|---|
| Started | 22 |
| Completed | 1 |
| Not completed | 21 |
| Withdrew: Adverse event | 1 |
| Withdrew: Other | 4 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Lack of efficacy | 14 |
Median Tmax = time for maximum plasma concentration (Cmax) for SU011248, SU012662, and combined SU011248 and SU012662 (total drug); collected C1D2, C2D3. Paired observation.
| hours | Sunitinib in Combination With Docetaxel |
|---|---|
| SU011248 C1D2 | 6.0 (4.0 to 24.0) |
| SU011248 C2D3 | 6.0 (2.0 to 8.0) |
| SU012662 C1D2 | 6.0 (2.0 to 24.0) |
| SU012662 C2D3 | 6.0 (4.0 to 24.0) |
| Total drug C1D2 | 6.0 (2.0 to 24.0) |
| Total drug C2D3 | 6.0 (2.0 to 8.0) |
Mean Cmax = maximum plasma concentration for SU011248, SU012662, and combined SU011248 and SU012662 (total drug) measured as nanograms per milliliter (ng/mL); collected C1D2, C2D3. Paired observation; Cmax dose corrected C2D3 (dose correction if predose concentrations of SU011248 or SU012662 were \> 5% of Cmax).
| ng/mL | Sunitinib in Combination With Docetaxel |
|---|---|
| SU011248 C1D2 | 29.17 ± 7.906 |
| SU011248 C2D3 | 29.49 ± 7.910 |
| SU012662 C1D2 | 5.07 ± 2.385 |
| SU012662 C2D3 | 5.91 ± 2.251 |
| Total drug C1D2 | 34.05 ± 9.312 |
| Total drug C2D3 | 34.69 ± 8.941 |
Mean AUC24 = area under plasma concentration-time profile from time 0 to 24 hours for SU011248, SU012662, and combined SU011248 and SU012662 (total drug) measured in nanograms times hour per milliliter (ng\*hr/mL); collected C1D2, C2D3. Paired observation; AUC24 dose corrected C2D3 (dose correction if predose concentrations of SU011248 or SU012662 were \> 5% of Cmax).
| ng*hr/mL | Sunitinib in Combination With Docetaxel |
|---|---|
| SU011248 C1D2 | 486.38 ± 132.439 |
| SU011248 C2D3 | 479.80 ± 128.718 |
| SU012662 C1D2 | 82.21 ± 33.204 |
| SU012662 C2D3 | 96.88 ± 30.513 |
| Total drug C1D2 | 568.78 ± 152.106 |
| Total drug C2D3 | 567.43 ± 145.952 |
Mean AUClast = area under the plasma concentration-time profile from time 0 (predose) to the last measurable concentration; collected C1D2, C2D3. Data did not allow calculation of AUClast; not summarized; AUC summarized in outcome measure: Area under the plasma concentration-time curve from time zero (0) to 24 hours (AUC24): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters.
No measurements were reported for this outcome.
Mean Ctrough=plasma concentration-time profile at time 0 (predose); collected C1D2, C1D15, and C2D1. Calculated by setting concentration values below the limit of quantification to zero.
| ng/mL | Sunitinib in Combination With Docetaxel |
|---|---|
| SU011248 C1D15 (n=18) | 52.06 ± 23.05 |
| SU011248 C2D1 (n=11) | 5.00 ± 5.14 |
| SU012662 C1D15 (n=18) | 21.75 ± 8.85 |
| SU012662 C2D1 (n=11) | 4.88 ± 3.52 |
| Total drug C1D2 (n=12) | 0.20 ± 0.00 |
| Total drug C1D15 (n=18) | 73.81 ± 29.00 |
| Total drug 21D1 (n=11) | 9.87 ± 8.36 |
Median Tmax = time to maximum plasma concentration (Cmax) for Docetaxel; collected C1D1, C2D1. Paired observation.
| hours | Sunitinib in Combination With Docetaxel |
|---|---|
| C1D1 | 0.70 (0.5 to 1.0) |
| C2D1 | 0.77 (0.5 to 1.0) |
Mean Cmax = maximum plasma concentration for Docetaxel; collected C1D1, C2D1. Paired observation; Cmax dose corrected (dose correction if predose concentrations of SU011248 or SU012662 were \> 5% of Cmax).
| ng/mL | Sunitinib in Combination With Docetaxel |
|---|---|
| C1D1 | 2932.00 ± 903.952 |
| C2D1 | 2955.38 ± 853.925 |
Mean AUC24 = area under the plasma concentration-time profile from time 0 to 24 hours; collected C1D1, C2D1. Paired observation.
| ng*hr/mL | Sunitinib in Combination With Docetaxel |
|---|---|
| C1D1 | 2918.09 ± 594.227 |
| C2D1 | 3101.69 ± 778.041 |
Median time (50 percent \[%\]) from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first; based on Investigator assessment. PFS calculated as (Weeks) = (first event date minus first dose date plus 1) divided by 7.
| weeks | Sunitinib in Combination With Docetaxel |
|---|---|
| Progression-Free Survival (PFS) Based on Investigator Assessment | 34.9 (28.1 to 55.6) |
Number of subjects with objective response based on Investigator assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response.
| participants | Sunitinib in Combination With Docetaxel |
|---|---|
| Number of Subjects With Objective Response of Complete Response or Partial Response Based on Investigator Assessment | 14 (90.9 to —) |
Number of subjects with clinical benefit based on Investigator assessment of confirmed complete response (CR), partial response (PR), or stable disease (SD) according to RECIST for at least 24 weeks on study.
| participants | Sunitinib in Combination With Docetaxel |
|---|---|
| Number of Subjects With Clinical Benefit of Complete Response, Partial Response, or Stable Disease Based on Investigator Assessment | 17 |
Median duration (50%) of tumor response based on Investigator assessment for a subgroup of subjects with objective disease response: who have not progressed or died due to any cause; with a response and subsequent progression or death due to any cause for duration of response (DR). DR defined as time from start of first documented objective tumor response (CR or PR) to first documented objective tumor progression or death due to any cause, whichever occurs first. DR calculated as (Weeks) = (the end date for DR minus first subsequent confirmed CR or PR plus 1) divided by 7.
| weeks | Sunitinib in Combination With Docetaxel |
|---|---|
| Duration of Tumor Response Based on Investigator Assessment | 28.7 (22.7 to 69.6) |
Mean AUC48 = area under the plasma concentration-time profile from time 0 to 48 hours; collected C1D1, C2D1. Paired observation.
| ng*hr.mL | Sunitinib in Combination With Docetaxel |
|---|---|
| C1D1 | 3167.53 ± 658.124 |
| C2D1 | 3326.98 ± 775.599 |
Mean AUC24_48 = area under the plasma concentration-time profile from 24 to 48 hours; collected C1D1, C2D1. Paired observation.
| ng*hr/mL | Sunitinib in Combination With Docetaxel |
|---|---|
| C1D1 | 249.45 ± 108.911 |
| C2D1 | 225.29 ± 96.657 |
Mean AUClast = area under the plasma concentration-time profile from time 0 (predose) to the last measurable concentration; collected C1D1, C2D1. Paired observation.
| ng*hr/mL | Sunitinib in Combination With Docetaxel |
|---|---|
| C1D1 | 3159.58 ± 675.834 |
| C2D1 | 3304.48 ± 769.011 |
Mean Thalf (t1/2) = terminal elimination half life; collected C1D1, C2D1. Paired observation.
| hours | Sunitinib in Combination With Docetaxel |
|---|---|
| C1D1 | 22.55 ± 5.914 |
| C2D1 | 24.88 ± 10.651 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sunitinib in Combination With Docetaxel | — | 11/22 (50%) | 21/22 (95.5%) |
| Event | Sunitinib in Combination With Docetaxel |
|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 4/22 |
| NeutropeniaBlood and lymphatic system disorders | 2/22 |
| LeukopeniaBlood and lymphatic system disorders | 1/22 |
| StomatitisGastrointestinal disorders | 1/22 |
| FatigueGeneral disorders | 1/22 |
| Oedema peripheralGeneral disorders | 1/22 |
| PyrexiaGeneral disorders | 1/22 |
| JaundiceHepatobiliary disorders | 1/22 |
| Back painMusculoskeletal and connective tissue disorders | 1/22 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 1/22 |
| Event | Sunitinib in Combination With Docetaxel |
|---|---|
| DiarrhoeaGastrointestinal disorders | 13/22 |
| AlopeciaSkin and subcutaneous tissue disorders | 12/22 |
| NauseaGastrointestinal disorders | 11/22 |
| StomatitisGastrointestinal disorders | 11/22 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 11/22 |
| NeutropeniaBlood and lymphatic system disorders | 10/22 |
| FatigueGeneral disorders | 10/22 |
| Mucosal inflammationGeneral disorders | 9/22 |
| HeadacheNervous system disorders | 8/22 |
| Abdominal pain upperGastrointestinal disorders | 7/22 |
| Age, Customized(participants) | Sunitinib in Combination With Docetaxel |
|---|---|
| 18 to 44 years | 3 |
| 45 to 64 years | 13 |
| > = 65 years | 6 |
| Sex: Female, Male(Participants) | Sunitinib in Combination With Docetaxel |
|---|---|
| Female | 21 |
| Male | 1 |
The record gives a start of Jul 2006, a primary completion of Oct 2008 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2009, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sunitinib · Docetaxel